Form 4: Casdin Capital Increases Stake in 2seventy bio, Inc. with $203,992 Purchase

Casdin Capital, along with related entities and Eli Casdin, reports acquiring 40,000 shares of 2seventy bio, Inc. at an average price of $5.0998 per share, increasing their indirect holdings.

Summary

• Casdin Capital, LLC, along with Casdin Partners Master Fund, L.P., Casdin Partners GP, LLC, and Eli Casdin, filed a Form 4 detailing changes in beneficial ownership of 2seventy bio, Inc. (TSVT) stock.
• On March 26, 2024, Casdin Partners Master Fund, L.P. purchased 40,000 shares of common stock at a weighted average price of $5.0998, totaling approximately $203,992.
• The purchase price ranged from $4.9 to $5.41 per share.
• Following the transaction, the Master Fund indirectly holds 2,000,000 shares.
• Eli Casdin also directly owns 16,600 shares of common stock.
• Eli Casdin has been deputized to represent the Reporting Persons on the board of directors of the Issuer.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock purchase by a significant shareholder, indicating continued investment but without specific positive or negative implications.

Positives

• Increased investment by Casdin Capital may signal confidence in 2seventy bio, Inc.'s future prospects.
• The purchase increases Casdin's stake in the company.

Management Comments

• Eli Casdin has been deputized to represent the Reporting Persons on the board of directors of the Issuer.
• Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to the market.

Stakeholder Impact

• The increased stake by Casdin Capital could be viewed positively by shareholders.

Key Dates